Evolocumab for cholesterol: After one year, patients on new drug fare better than standard therapy

16 marzo 2015

Patients taking evolocumab — an investigational therapy previously shown to dramatically lower ‘bad’ cholesterol — were half as likely to die, suffer a heart attack or stroke, be hospitalized or need a procedure to open blocked arteries compared with those who received standard care, according to new research.